Neion Bio Emerges from Stealth with Multi-Product Biosimilar Partnership Leveraging Its Cutting-Edge Genetic Engineering PlatformNEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced its emergence from stealth and the signing of its first co-development and supply agreement with a major global pharmaceutical company. Neion’s Raptor™ platform utilizes the latest genetic engineering tools to produce recombinant biologics in eggs, enabling scalable and efficient production of virtually any therapeutic protein. This commercial deal provides Neion with near-term revenue through up-front and milestone payments, along with long-term participation through profit sharing once products are commercialized.
